Tag Archives: MTC

PR Newswire

Waterdrop Co-founder Yao Hu Shares Progress in Pharmaceutical Innovation

Leave a comment

BEIJING, Nov. 18, 2022 /PRNewswire/ — On November 16, Mr. Yao Hu, co-founder of Waterdrop and General Manager of the Pharmaceutical Innovation Business Unit, attended the Jiemian(Jiemian.com) Big Health Forum 2022 sponsored by Shanghai United Media Group, at which he shared the exploration and headway Waterdrop has made in pharmaceutical innovation over the last two years.

Hu said, Waterdrop has made “bringing insurance and healthcare service to billions through technology” its mission since it was established in 2016. Over the last six years, it has worked to make medical treatment affordable to patients and served over 110 million customers through a wide range of health insurance products. It also launched Waterdrop Medical Crowdfunding, which helped 2.58 million patients with severe critical illness raise RMB53.3 billion of funds and eased the financial pressure on those in difficulties.  

While serving patients, Waterdrop has developed a chain of healthcare-related services and launched the pharmaceutical innovation service to offer platforms for the pharmaceutical industry.

Currently, Waterdrop’s pharmaceutical innovation service centers on three platforms, i.e. Waterdrop Patient Platform, Digital Marketing Platform, and E-find (E-find Recruitment and E-find CRO).

Hu gave a detailed introduction to E-find, which features a professional team, fast patient enrollment into clinical trial groups, a competitive platform, and digital operation. Relying on the strengths, E-find Patient Recruitment has grown into a leading third-party patient recruitment platform at home in just two years, with a highly competitive edge in the tumor field. As an Internet tech enterprise, Waterdrop boasts strong capabilities in digitalizing patient screening for research centers, subject compensation, the match between patients and projects, and follow-up visits to subjects.

Waterdrop Patient Platform commits to building a full-lifecycle service system for patients with critical illnesses. The digital marketing platform provides pharmaceutical enterprises with services like market potential evaluation and precise and comprehensive market surveys, to help partners develop targeted marketing strategies and complete digital marketing efficiently and precisely.

Hu said, “Focusing on millions of patients with severe illness, Waterdrop’s pharmaceutical innovation service aims to speed up the R&D of innovative drugs and promote digital marketing for pharmaceutical enterprises. Over the past two years, we’ve carried out remarkable strategic cooperations with countless pharmaceutical enterprises and research institutes. Going forward, we expect to engage with more partners to deliver more fruitful results.”

About Waterdrop Inc.

Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit www.waterdrop-inc.com.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about Waterdrop’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in Waterdrop’s filings with the SEC. All information provided in this press release is as of the date of this press release, and Waterdrop does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Cision View original content:https://www.prnewswire.com/news-releases/waterdrop-co-founder-yao-hu-shares-progress-in-pharmaceutical-innovation-301682542.html

Source: Waterdrop Inc.

PR Newswire

World Stroke Organization Tackle Gaps in Access to Quality Stroke Care

Leave a comment

GENEVA, Switzerland, Oct. 28, 2022 /PRNewswire/ — On World Stroke Day (29th Oct), the World Stroke Organization has announced the launch of a new program that aims to drive access to quality acute stroke care and save lives around the world.

What happens in the minutes after someone has a #stroke? They start to lose crucial brain tissue that contains memories, language and personality. Knowing the symptoms and acting FAST can save that person’s life.Learn the signs, Say it’s a stroke. Save #Precioustime
What happens in the minutes after someone has a #stroke? They start to lose crucial brain tissue that contains memories, language and personality. Knowing the symptoms and acting FAST can save that person’s life.Learn the signs, Say it’s a stroke. Save #Precioustime

The WSO Stroke Certification initiative is a strategic response to the results of a WHO-WSO survey which found that less than half (49%) of countries could provide comprehensive evidence-based acute stroke care. The survey also identified a huge gap in provision of care between high- and low- and middle-income countries. While 91% of high-income countries were able to provide access to specialist stroke unit care, the number was just 8% in low-income countries. 

Two of the fundamental markers of quality acute stroke care are the provision of thrombolysis (the removal of blood clots using intravenous medication) and thrombectomy (the removal of blood clots by keyhole surgery). Research published by WSO found global rates of access to these treatments stand at 46% and 30% respectively.

‘One in four of us will have a stroke in our lifetime, yet the majority of people globally lack access to effective treatment and stroke center care. On top of this, a lack of effective global prevention strategies has led us to a place where stroke is the second leading cause of death and the third leading cause of disability worldwide, with a soaring human and economic cost,’ said WSO President Professor Marc Fisher. Incoming WSO President and leading Brazilian neurologist, Professor Sheila Martins added: ‘We have the knowledge and tools that could save millions of lives and hundreds of millions of dollars. Delivering quality stroke care is not just the right thing to do, it’s the smart thing to do.’

WSO’s Global Stroke Guidelines and Action Plan aim to help institutions and governments implement evidence-based criteria and standards for care developed by WSO. Initially targeting hospitals in middle-income countries, the program will be launched on Nov 1st with the primary aim of growing the global network of accredited stroke care providers.

Stroke is a leading cause of death and disability worldwide. On World Stroke Day the public, health care professionals, stroke survivors, politicians and industry leaders will come together to raise awareness of stroke symptoms and the importance of timely treatment.  

The public can follow the campaign on social media using #Precioustime and help raise awareness by sharing a clock selfie or participating in the strokespotter.org online game challenge.

Notes to Editors

I. The World Stroke Organization is the only global body solely focused on stroke. With around 3000 individual and 100 society members, spanning every global region, we represent over 55,000 stroke specialists in clinical research and support services. WSO is in official relations with WHO and has UN consultative status.
II. The WSO Stroke Certification program builds on the WSO-SIEVC Certification program in Latin America and the Caribbean https://www.world-stroke.org/news-and-blog/news/wso-siecv-certification-of-stroke-centers-in-latin-america-and-caribbean
III. State of stroke services across the globe https://journals.sagepub.com/doi/abs/10.1177/17474930211019568 
IV. WSO Global Stoke Factsheet https://www.world-stroke.org/publications-and-resources/resources/global-stroke-fact-sheet 
V. World Stroke Day website www.worldstrokecampaign.org

Contacts:

Anita Wiseman,
Campaign & Partnerships Manager, WSO
campaign@world-stroke.org
+447940029444

Knowing the symptoms and signs of a #stroke and acting #FAST can save a person’s life and all the things that make them unique.Learn the signs, Say it’s a stroke. Save #Precioustime
Knowing the symptoms and signs of a #stroke and acting #FAST can save a person’s life and all the things that make them unique.Learn the signs, Say it’s a stroke. Save #Precioustime
PR Newswire

Biomedical industry bears fruit again in National Nanning Economic & Technological Development Area

Leave a comment

NANNING, China, Aug. 31, 2022 /PRNewswire/ — Recently, the lung CT image-aided diagnosis software developed by Guangxi Yizhun Intelligent Technology Co., Ltd. (“Yizhun”) in National Nanning Economic & Technological Development Area (“Area”) has been granted the registration certificate of class III medical devices (GXZZ20223210687).

Production workshop of Nanning Neptunus Health Industrial Park
Production workshop of Nanning Neptunus Health Industrial Park

Nanning’s investment promotion departments at all levels aim at creating biomedical industry clusters through high starting point planning and attraction of targeted investments, according to National Nanning Economic & Technological Development Area Management Committee. In the Area, the biomedical industry, involving the fields of production, inspection & testing, sales and distribution, continually expands in industrial scale and gradually improves in industrial chain. The approved “lung CT image-aided diagnosis software” is the first software in Guangxi province and the country’s eighth one with the registration certificate of class III AI medical devices and software, and the sixth in Guangxi province and the second in Nanning city to have received the certificate. This is another achievement of the city’s continuous optimization of services for moved-in enterprises and solid efforts in building up the biopharmaceutical industry.

In terms of precise investments, the Area has compiled a panorama of biopharmaceutical industry chain, positively brought in investments in the industry chain and industry clusters and introduced a batch of key projects such as Hainan Huluwa Pharmaceutical, Guangdong Yili Pharmaceutical, Yida Xiansheng, Sinopharm Group and Guangxi LiuYao Group, forming an industrial development pattern with biopharmaceuticals, traditional Chinese medicine, health care products, medical devices and modern pharmaceutical logistics as main fields. According to information, the Area is the major ground to develop the biopharmaceutical industry in the city, and there are currently 625 biopharmaceutical enterprises in the Area.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=428269
   Caption: Production workshop of Nanning Neptunus Health Industrial Park

Source: National Nanning Economic & Technological Development Area Management Committee

PR Newswire

Lunit Announces Financial Results for the First Half of 2022

Leave a comment

  • Consolidated revenue in the second quarter of 2022 increased by 190% compared to same prior-year period
  • Total revenue for H1 2022 amounted to KRW 5.48 billion, or 82.5% of the total revenue of last year

SEOUL, South Korea, Aug. 12, 2022 /PRNewswire/ — Lunit (KRX: 328130.KQ), a global provider of AI-powered cancer solutions, today announced strong financial results for the second quarter of the fiscal year 2022.

“Through a strong overseas performance in the first half of this year, Lunit achieved more than 80% of last year’s total sales within the first half of 2022,” said Brandon Suh, CEO of Lunit. “With more partnerships to come and the annual health examination season coming up in the third and fourth quarters, we expect our revenue to increase significantly during the second half of the year.”

Reporting under a consolidated basis, Lunit recorded a cumulative revenue of KRW 5.48 billion for the first half of 2022, reaching 82.5% of total sales for the previous year. H1 revenue for 2022 more than tripled compared to the same prior-year period (KRW 1.42 billion) and the proportion of overseas sales jumped from 66.8% to 84.3% year-over-year.

Lunit’s second quarter 2022 revenue was KRW 2.51 billion, up 190% from the prior-year period (KRW 863 million), among which overseas revenue accounted for 80.6%.

H1 Fiscal 2022 Summary

KRW in
millions

H1 2022

Revenue
proportion

H1 2021

Y/Y

Total revenue

5,478

100 %

1,402

Up 291%

Overseas

4,619

84.3 %

937

Up 393%

Domestic

859

15.7 %

465

Up 84.7%

About Lunit

Lunit is a medical AI software company devoted to developing AI solutions for precision diagnostics and treatment support, mainly focused on conquering cancer.

Lunit has partnered with global medical device giants such as GE Healthcare, Philips, and FujiFilm. The company also focuses on its biomarker business through an exclusive partnership with Guardant Health, a leading global liquid biopsy company.

Lunit has earned international recognition for its unprecedented, state-of-the-art AI technology. More than half of its employees are research and development (R&D) specialists, with more than 12 medical doctors working as full-time staff.

Lunit’s flagship products are Lunit INSIGHT and Lunit SCOPE. The FDA-cleared and CE-marked Lunit INSIGHT series provide AI-powered detection of chest abnormalities and breast cancer with 96-99% accuracy. As of March 2022, Lunit INSIGHT products are being used in approximately 600 medical sites in more than 40 countries. Lunit SCOPE series provide AI detection and analytics for tissue data, quantifying key features and scores that enhance elevated response prediction for immunotherapy. By receiving CE Mark in April 2022, Lunit SCOPE PD-L1 TPS has been officially approved for deployment and use in European pathology practices.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lunit-announces-financial-results-for-the-first-half-of-2022-301604990.html

PR Newswire

Vela Diagnostics Develops PCR-based Test for Detecting Monkeypox Virus

Leave a comment

SINGAPORE, July 26, 2022 /PRNewswire/ —  Vela Diagnostics announced that it has developed a PCR test kit to detect the monkeypox virus (MPXV), for research use only (RUO).

The ViroKey® MPXV PCR Test allows for the prompt, in vitro detection of MPXV DNA from human skin lesion specimens. It is compatible with common real-time PCR cyclers, such as the Rotor-Gene Q and Applied Biosystems 7500 series platforms. In silico testing shows that the assay is specific for MPXV and has no cross-reactivity with other orthopoxviruses.

“We worked closely with our customers to develop a test that is specifically designed to meet their requirements, making sure that they have a monkeypox-specific assay, with maximum flexibility to choose between manual and automated workflows depending on the number of samples they receive,” said Dr Charlie Lee, Head of Research and Development at Vela Diagnostics.

The monkeypox outbreak has been declared a global health emergency by the World Health Organization (WHO), with over 16,000 cases worldwide. The mode of transmission is thought to be close, sustained physical contact with other people who have monkeypox. The WHO has requested for all countries to provide testing for any individuals that meet the suspected case definition, and to immediately notify it in the case of positive laboratory results.

“Throughout the COVID-19 pandemic, we have worked closely with various testing labs across the globe. We responded quickly to the monkeypox epidemic by allowing research partners and laboratories to offer timely and accurate monkeypox testing,” said Sam Dajani, CEO of Vela Diagnostics and Chairman of the Board. “We have already released the first few batches of kits, and they are being evaluated by our customers globally. We are committed to increasing testing capacity of monkeypox in hopes of containing the spread of the virus.”

For more information; including the IFU, please contact us.

About Vela Diagnostics

Vela Diagnostics is a leading provider for integrated IVD system solutions, from sample to result. VELA’s test solutions utilize the automated SentosaTM platform, providing the unique ability to leverage one system for NGS and PCR testing in infectious disease and oncology.

All Sentosa products listed above are by Vela Diagnostics. For more information, visit www.veladx.com. All other product names, trademarks and logos are the property of their respective owners.

Cision View original content:https://www.prnewswire.com/news-releases/vela-diagnostics-develops-pcr-based-test-for-detecting-monkeypox-virus-301593161.html

PR Newswire

Insurance providers can assess customer health risks in real-time using contactless vital sign monitoring solution from NuraLogix

Leave a comment

LAS VEGAS, June 29, 2022 /PRNewswire/ — Insurance providers are now able to evaluate customer health risks in real-time using a revolutionary contactless wellness and vital sign monitoring solution from NuraLogix. 

The application allows insurance providers to quickly perform a customer health check during the online interview process using a web-browser. The NuraLogix technology uses a conventional video camera to extract blood flow information from the face, in a patented process called Transdermal Optical Imaging (TOI™), resulting in more than 30+ medical grade health and wellness measurements.

The NuraLogix technology was available for demonstration at the America’s Health Insurance Plans (AHIP) show in Las Vegas, Nevada from June 21 to 23.

The benefits of integrating a vital sign monitoring system into the insurance evaluation process are numerous: reduced costs of underwriting a policy, no nurses needed to conduct physical examinations or take fluid samples, improved compliance with the terms of lower-cost standard policies to avoid price increases, and more. This technology has also been shown to create a ‘Sentinel Effect,’ reducing fraud and improving the accuracy of questionnaire responses.

The Background

Currently in the insurance industry, providers calculate premiums for users, the amount users pay in exchange for coverage. Insurance premiums are based on a wide variety of factors such as age, gender, risk, type of coverage, location, and more. Providers calculate the likelihood the user will need to use the insurance, for example, younger people are less likely to need medical care, so their premiums are generally cheaper. Integrating the NuraLogix technology into the risk evaluation process allows insurers to calculate premiums using accurate health data of the individual and potentially even provide incentives to get healthier.

About AHIP 2022

America’s Health Insurance Plans (AHIP) is the national association of nearly 1,300 members who provide healthcare insurance to more than 200 million Americans. As a national trade association in the health insurance industry, AHIP lobbies to create a more affordable healthcare system through research and policy. Their conference, AHIP 2022, (Formerly ‘Institute & Expo’) brings together the people, ideas, and solutions that guide greater health.

About NuraLogix

NuraLogix’s technology is based on extensive peer-reviewed research and clinical studies, a fact which differentiates them from their competitors. NuraLogix has conducted multiple clinical studies and published research in many notable publications such as Frontiers in Psychology, Scientific Reports, and the Journal of Natural Sciences (JNS). NuraLogix currently holds 11 patents, with more pending. Their impressive client roster includes Japanese systems integration leader NTT Data; Sanitas, the second largest medical insurance company in Spain; and Lafiya Telehealth, a Nigerian-based health telehealth platform which provides 24/7 virtual healthcare services to residents in remote and rural areas.

To Learn More:

Visit our website:
NuraLogix – https://www.nuralogix.ai/  

Disclaimers:

Note: In the United States, this product is for Investigational Use only. The performance characteristics of this product have not been established.

For Media Inquiries: Chris Lin, Chief Marketing Officer, ChrisLin@nuralogix.ai , Tel: 437-928-2666

PR Newswire

IFN Neurologic and MetaCell Partner to Launch the IFN Neurologic Affiliate Program

Leave a comment

CAMBRIDGE, Mass., and PERTH, Australia, June 28, 2022 /PRNewswire/ —

Summary

The Institute of Functional Neuroscience, a world leading treatment and rehabilitation centre utilising the latest technologies in neuroplasticity research, and MetaCell, an innovative life science software company specialised in cutting-edge research software for major pharma, biotech, and academic institutions, have partnered to launch IFN Neurologic. This application will help clinicians to better serve patients with neurological disorders and provide treatments in the functional neuroscience domain. The application has been piloted with a limited number of clinics in 2021/2022, and now is made available to clinics and patients worldwide.

IFN Neurologic is an innovative application to help clinicians better serve patients with neurological disorders and provide treatments in the functional neuroscience domain
IFN Neurologic is an innovative application to help clinicians better serve patients with neurological disorders and provide treatments in the functional neuroscience domain

Affiliate Program 

Affiliate clinics will use for the first time IFN Neurologic to perform restorative neuroplasticity interventions on their patients at their own clinic. The affiliate program includes a comprehensive education program accredited by IFN (Institute of Functional Neuroscience) and AICN (Australian Institute of Clinical Neuroscience), all the necessary hardware/software, and access to the IFN Neurologic platform.

The team

Dr. Randy Beck, PhD, Director of the IFN, said: “We’re excited to be launching this new application in partnership with MetaCell. With this new software that requires no installation and can be reached from any web browser in the world, we now have the ability to rapidly scale up our diagnostic processes and reach more patients around the world at the click of a button.”

Giovanni Idili, COO of MetaCell, added: “We are very proud to work with Dr. Beck and provide IFN with a solution that ultimately allows the organisation to help a much greater number of patients at the same outstanding level of service, and we look forward to partnering with many more clinical innovators using our unique approach to custom software development in concert with our clinical neuroscience platforms.”

About IFN

The Institute of Functional Neuroscience (IFN) utilises the latest in neuroplasticity and neuroscience research to develop treatment approaches aimed at improving brain and nervous system performance of patients with a wide range of conditions including migraines, seizure disorders, strokes, attention deficit disorders, obsessive compulsive disorder, developmental coordination delay, vertigo, depression, learning and developmental disorders, concussion syndromes and autism.

About MetaCell

MetaCell is a life science-focused software company composed of scientists and software engineers, with deep domain expertise in computational neuroscience, molecular biology, data science, and enterprise-grade online software development. Their solutions have been trusted for over a decade by some of the world’s largest pharmaceutical companies and leading research institutions in the USA, UK, Australia, Canada, and Europe, including Biogen, Pfizer, Eisai, Salk, UCL, Mount Sinai, UCSD, Yale, Princeton, and many more.

Contact details

IFN Neurologic: https://ifnneurologic.com/ | +61 (08) 6254 2282 | affiliateprogram@ifnneurologic.com
IFN: https://ifn.net.au | +61 (08) 6254 2282 | info@ifn.net.au 
MetaCell: https://metacell.us/ | US +1 617-286-4832 | UK +44 1865 648684 | info@metacell.us

PR Newswire

Stryker’s debut at World Intelligence Congress: Bringing Stryker’s Advanced Digital Healthcare to China

Leave a comment

SHANGHAI, June 24, 2022 /PRNewswire/ — Stryker (NYSE:SYK), a leading medical technologies company, attended the 6th World Intelligence Congress (WIC) in China, showcasing how its Advanced Digital Healthcare solutions brings clinical, operational and financial values for the healthcare market. This is the first time for Stryker to participate in WIC as a strategic partner in healthcare industry, marking a significant milestone for Stryker as it brings more Advanced Digital Healthcare solutions to the China market.

Statistical Communiqué of The People’s Republic of China on the 2021 National Economic and Social Development shows that over 14.2% of the population, or 200,000,000 people are aged 65 and above, increased by 0.7% compared with that in 2020. The aging population in China presented ever pressing demands for China’s health industry, in which digital technology has a key role to play in achieving “health inclusivity” and “cost reduction and efficiency improvement.”

Stryker has a centralized technology organization called Digital, Robotics, and Enabling Technologies (DRE), dedicated to accelerating innovations across the enterprise.  By enabling its innovative products with digital capabilities, Stryker is generating insights to drive improved clinical, operational and financial outcomes across the patient care pathway.


“We are in the world of specialization focused on each stage of the patient care pathway from transport to diagnosis to planning and the OR, to recovery and monitoring, and then rehab and follow up,” says Robert Cohen, President of Digital, Robotics, and Enabling Technologies at Stryker. “We are keen to bring more of our Advanced Digital Healthcare solutions to China.”

One of the highlights of our Advanced Digital Healthcare breakthroughs is Mako SmartRobotics™, a highly advanced robotics technology that transformed the way total knee, partial knee and hip replacements are performed. Mako is able to provide a personalized surgical plan based on your unique anatomy and allow doctors to cut less by cutting precisely. Mako is poised to play a bigger role in making healthcare available for more patients in China through 5G technology. In China, Stryker also provides digital MedSurg solutions in endoscopy: – 1688 andPinPoint, instruments: Core2.0 and Signature and Sonopet, Hololens – Hololens glasses and HI-Integrated surgery room solution.


“China is the second largest healthcare market in the world, and we have been witnessing booming digital healthcare development here. We are committed to working with local partners to bring more technologies to realization and benefit Chinese patients,” says Greg Holman, President of Stryker China.

Stryker has over 85 global digital solutions that span the patient care pathway. We are dedicated to bringing the “best of Stryker” to customers in China, a strategic market for Stryker’s global strategy. Stryker continues to live up to its promise of “grow with China” as it plays a leading role in digital innovation, introducing Advanced Digital Healthcare—innovation that empowers outcomes to China. Stryker is committed to developing healthcare solutions that fit the local market, and expand local partnerships to build an enabling ecosystem. We’re passionate about digital innovation and helping our customers deliver improved outcomes—today and tomorrow.

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 100 million patients annually. More information is available at www.stryker.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/strykers-debut-at-world-intelligence-congress-bringing-strykers-advanced-digital-healthcare-to-china-301574632.html

PR Newswire

First AI to Refine Medical Coding by Exploring Therapeutic Data

Leave a comment

SAN FRANCISCO, June 2, 2022 /PRNewswire/ — Medical AI start-up Aesop Technology announced a new partnership that made their new product, DxPrime, available in the Olive Library. DxPrime provides physicians and clinical documentation improvement (CDI) teams with information about missing and wrongly coded diagnoses and procedures to correct the patient’s chart in just a few clicks. It makes completing discharge summaries, prioritizing work for CDI teams, and medical coding much easier, faster, and less error-prone.

If the patient record is incorrect, you cannot code correctly.

Completeness, precision, and validity of medical documentation are critical for all healthcare stakeholders. Without correct patient records, patients could receive improper discharge instructions and a sub-optimal continuum of care. Providers also can struggle to estimate the length of stay and code insurance claims correctly, resulting in denials and loss of revenue.

Approximately 10% of inpatient claims are denied, of which more than 85% (or about $35 billion) result in unnecessary losses. Many of these denials occur because of errors in the patient record that occur upstream from the claims process. Diagnosis input errors are difficult for physicians to avoid because the knowledge of coding systems is different from what they need to learn to provide great patient care. Modern medicine’s complexity has caused 14,400 diseases to be included in ICD-10, further classified into 68,000 ICD-10-CM and 87,000 ICD-10-PCS codes.

“Physicians, CDI team, and coders have to spend a lot of time poring through medical records to find the key clinical diagnoses among the vast amount of information available,” said Jim Long, CEO of AESOP. “After that, they have to follow a series of inefficient steps on the computer to complete the input process, and search functionality for ICD codes often is not helpful. The whole process is complex, time-consuming, and error-prone.

When the physicians input the improper diagnosis, it also has downstream implications. When using DxPrime, we have helped physicians often notice they did not correctly code complications such as urinary tract infections and respiratory failure. By assisting them in inputting the proper diagnoses, our partners have seen an increase in revenue of 5-10% per inpatient.”

State-of-the-art machine learning assisted physician data entry.

DxPrime provides high-quality suggestions to support physician data entry based on a machine learning model (published in the Healthcare journal) that has been run on top of data from 3.2 Billion patient visits, including vast amounts of structured information. It allows DxPrime to use items from the patient record like lab test results and medications ordered when predicting a diagnosis.

This comprehensive model utilizes artificial intelligence to efficiently compensate for traditional CDSS and NLP weaknesses to find correct or missed diagnoses.

About Aesop Technology

Aesop Technology develops AI-powered technology to enhance patient safety and medical coding quality.

Contact
Jeremiah Scholl, CPO & Co-founder
hi@aesoptek.com
T: +1 415-818-0633
www.aesoptek.com

Cision View original content:https://www.prnewswire.com/news-releases/first-ai-to-refine-medical-coding-by-exploring-therapeutic-data-301559368.html

PR Newswire

Panoramic Atlases of Life Published in Cell Mark Establishment of SpatioTemporal Omics Consortium

Leave a comment

STOC launches with more than 80 scientists joining globally, focused on obtaining the greatest scientific benefits from spatially resolved transcriptomics technology; first studies use BGI-Research’s Stereo-seq to produce spatiotemporal cellular maps of mice, Drosophila, zebrafish, and Arabidopsis

SHENZHEN, China, May 5, 2022 /PRNewswire/ — Scientists from 16 countries today announced the establishment of the SpatioTemporal Omics Consortium (STOC), an open scientific community focused on using spatially resolved cellular resolution omics technology to map and understand life. Their first studies resulted in state-of-the-art panoramic spatial atlases of life, published in Cell and Developmental Cell on May 4.

Over 80 scientists from Harvard University, Oxford University, MIT, University of Cambridge, the Karolinska Institutet, the University of Western Australia, the Genome Institute of Singapore, BGI-Research, among others, are collaborating as part of STOC. Members of the research group who produced the panoramic atlases used a new enabling technology Stereo-seq, developed by BGI-Research, to produce the most insightful spatiotemporal cellular maps to date of mice, small fruit flies (Drosophila), zebrafish, and the Arabidopsis plant, making a breakthrough in resolution and panoramic field of view and enabling analysis of the distribution and placement of molecules and cells in situ, and over time.

Identifying the characteristics of specific cells within a tissue has significant applications for understanding physiology, how organisms develop, and which cells are causes or indicators of disease, potentially leading to future gains in human disease research. These lay an important foundation for STOC’s research initiatives, which aim to create diverse sets of spatiotemporal atlases to broaden our knowledge of disease treatment, organ structures, development and aging, and to improve our understanding of biological evolution.

“In the last few years, there has been a lot of progress of mapping the genome and transcriptome in single cells. But this has been without the context of the spatial aspect of neighbourhoods of cells, ecosystem of cells, and therefore there is a whole layer of information that has been missing, which I think will now become accessible. That will have a major impact on both basic and translational research,” says Berthold Göttgens, Director of the Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, and a Member of STOC.

The transformational aspects of spatiotemporal omics for scientific research are captured in the goals of the STOC, as Weibin Liu, STOC Organizing Committee Member, explains.

“The panoramic atlases published late yesterday are the first steps toward the Consortium’s vision of revolutionizing humanity’s understanding of mind and body, youth and old age, health and illness, the origin and future of the human race, and the rest of the living world, for that matter,” says Liu. “They lay the groundwork for multiple atlases the Consortium could complete together, and they validate approaches for creating other spatiotemporal atlases.”

“Because of the magnitude of such endeavors, they require nothing short of a concerted global effort, across multiple disciplines from science to engineering to mathematics, and across diverse stakeholders from medicine to industry to funders. Together with our 80+ members so far, we will work to chart the way forward, to build new tools and competencies, to share resources and results, to map and solve the unknown,” he adds

The SpatioTemporal Omics Consortium (STOC) is an open, collaborative research initiative established to unite, organize, advance and share global scientific efforts in spatiotemporal omics to solve the mysteries of life. More information about STOC can be found at www.sto-consortium.org .